Eli Lilly hits pause on Aduhelm rival donanemab as execs fret about Medicare's skeptical stance on Alzheimer's drug class

Paul Schloesser

Associate Editor

While Biogen is still fighting to save its controversial drug Aduhelm from drowning in criticism, Eli Lilly execs echoed former FDA commissioner Scott Gottlieb’s comments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly hits pause on Aduhelm rival donanemab as execs fret about Medicare's skeptical stance on Alzheimer's drug class

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug class

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Eli Lilly hits pause on Aduhelm rival donanemab as execs fret about Medicare's skeptical stance on Alzheimer's drug class

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.